Literature DB >> 28961830

Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.

Y Q Li1, S S Song2, S H Jiang3, X Y Zhang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28961830     DOI： 10.1093/annonc/mdx324

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.

Authors:  Ka Wu; Chao Guo; Rong Li
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

2.  Unearthing EGFR Mutations and the Rewards of Persistence in Precision Oncology: Breaching the 10-Year Survival Barrier in Metastatic NSCLC With Active Disease.

Authors:  Pawan Kumar Singh; Rajender Kumar; Amanjit Bal; Nalini Gupta; Rakesh Kapoor; Kuruswamy Thurai Prasad; Navneet Singh
Journal:  JCO Glob Oncol       Date:  2020-02

Review 3.  Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer.

Authors:  Diego Kauffmann-Guerrero; Kathrin Kahnert; Rudolf M Huber
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.